BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer

Issue title: Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Guest editors: Jennifer Eng-Wongx and Jo Anne Zujewskiy

Article type: Research Article

Authors: Diaz-Cruz, Edgar S.^a | Cabrera, Marina C.^a | Nakles, Rebecca^a | Rutstein, Beth H.^a | Furth, Priscilla A.^{a; b; c; *}

Affiliations: [a] Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA | [b] Department of Medicine, Georgetown University, Washington, DC, USA | [c] WCU Research Center of Nanobiomedical Science, Dankook University, San 29, Anseo-Dong, Cheonan, 330-714, Korea | [x] Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA | [y] Clinical Trial Evaluation Program (CTEP), National Cancer Institute, Bethesda MD, USA

Correspondence: [*] Corresponding author: Priscilla A. Furth, MD, Lombardi Comprehensive Cancer Center, Georgetown University, Research Bldg. Room 520A, 3970 Reservoir Rd NW, Washington DC 20057, USA. Tel.: +1 202 687 8986; Fax: +1 202 687 7505; E-mail: paf3@georgetown.edu

Abstract: Genetically engineered mice along with allograft and xenograft models can be used to effectively model triple negative breast cancer both for studies of pathophysiology as well as preclinical prevention and therapeutic drug studies. In this review eight distinct genetically engineered mouse models of BRCA1 deficiency are discussed in relationship to the generation of triple negative mammary cancer. Allograft models derived from some of these genetically engineered mice are considered and xenograft models derived from breast cancers that developed from BRCA1 mutation are presented. Examples of the use of genetically engineered, allograft and xenografts models for preventive and therapeutic studies are presented.

Keywords: BRCA1, mouse models, triple negative breast cancer

DOI: 10.3233/BD-2010-0308

Journal: Breast Disease, vol. 32, no. 1-2, pp. 85-97, 2011